Written by The South America Non Alcoholic Steatohepatitis Biomarkers Market is expected to develop steadily through 2035 as healthcare providers focus on improving liver disease detection and monitoring. According to Market Research Future, the market is projected to grow from USD 15.35 million in 2025 to USD 19.39 million by 2035 at a CAGR of 2.36%.
The future outlook is closely linked to the increasing prevalence of obesity and metabolic disorders. These conditions are associated with a higher risk of NAFLD and NASH, creating a growing need for diagnostic tools that can support early identification and disease management.
Biomarker research is expected to remain a central area of development. Researchers are investigating new biological indicators that could improve the detection of fibrosis, inflammation, oxidative stress, and apoptosis. The development of accurate biomarkers may help healthcare providers obtain more detailed information about disease status.
Point-of-care testing is one potential future opportunity. Rapid diagnostic solutions could make biomarker testing more accessible, particularly in healthcare settings where advanced laboratory infrastructure may be limited. Such technologies could also support more frequent disease monitoring.
Artificial intelligence and machine learning may further influence the market. AI-assisted analysis can potentially help researchers process complex biological datasets and identify patterns associated with disease progression. Integration of AI with diagnostic technologies could support the development of more personalized approaches to NASH management.
Pharmaceutical companies and CROs are expected to remain important market participants. Biomarkers can support clinical trials, patient selection, drug development, and evaluation of therapeutic responses. Partnerships between pharmaceutical companies and regional research organizations could accelerate the development of new diagnostic solutions.
Brazil is likely to remain a key market because of increasing healthcare awareness and investment. Mexico and Argentina also present opportunities, while the Rest of South America could experience gradual development as healthcare infrastructure and regulatory support improve.
By 2035, the regional biomarker ecosystem could become more integrated with personalized medicine, digital healthcare, and advanced diagnostic platforms. Continued investment in research, regulatory development, healthcare infrastructure, and public awareness will be important for realizing the market’s potential.
Explore additional reports to understand evolving market landscapes:
Pigmentation Disorders Treatment Market Outlook
Clinical Oncology NGS Market Analysis